Quantcast

Latest Alkaloids Stories

2011-02-02 07:00:00

HUNTSVILLE, Ala., Feb. 2, 2011 /PRNewswire/ -- EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer. EGEN has successfully completed two Phase I trials of EGEN-001 in ovarian cancer patients. In the first study, EGEN-001 was administered...

2011-01-31 20:55:01

A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells. Chemists worldwide have been interested in lomaiviticin's potential anticancer properties since its discovery in 2001. But so far, they have been unable to obtain significant quantities of the compound, which is produced by a rare marine bacterium that cannot be...

2011-01-28 12:58:54

Taxol stabilizes growing nerve cells and reduces the barrier-function of scar tissue After a spinal cord injury a number of factors impede the regeneration of nerve cells. Two of the most important of these factors are the destabilization of the cytoskeleton and the development of scar tissue. While the former prevents regrowth of cells, the latter creates a barrier for severed nerve cells. Scientists of the Max Planck Institute of Neurobiology in Martinsried and their colleagues from the...

2011-01-18 06:30:00

CALGARY, Jan. 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN((R)) versus carboplatin and paclitaxel alone in the first line treatment of patients with...

2010-12-21 15:44:55

According to new study published in Pain The relationship between smoking and cancer is well established. In a study published in the January 2011 issue of Pain, researchers report evidence to suggest that cancer patients who continue to smoke despite their diagnosis experience greater pain than nonsmokers. They found that for a wide range of cancer types and for cancers in stages I to IV, smoking was associated with increased pain severity and the extent to which pain interfered with a...

2010-12-20 15:01:00

SAN DIEGO, Dec. 20, 2010 /PRNewswire/ -- Ambit Biosciences (Ambit), today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor. The Phase I trial for AC430 is a two part, placebo-controlled, single ascending, and multiple ascending dose trial in healthy volunteers. AC430 will be administered orally once-daily and doses escalated until a maximum tolerated or maximum feasible dose is...

2010-12-09 08:00:00

BRIDGEWATER, N.J., Dec. 9, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the final survival analysis (10-year follow-up) of the BCIRG001 study that included a Taxotere® (docetaxel) Injection Concentrate chemotherapy treatment regimen in the adjuvant breast cancer setting, as well as data from iniparib (BSI-201) pre-clinical and clinical breast cancer studies will be featured during the 33rd Annual San Antonio Breast...

2010-12-01 06:30:00

CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN((R)) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study is being sponsored by the Cancer Therapy...

2010-11-29 14:35:08

Scientists from Germany, UK and Italy identify a molecular switch that leads to a sustained increase of calcium in nerve cells and plays a crucial role in the formation of memory and addictive behaviors. Learning and memory formation are based on the creation of new connections between neurons in the brain. Also, behaviors such as nicotine addiction manifest themselves in long-term changes of neuronal connectivity and can "“ at least in this respect "“ be viewed as a form of...

2010-11-29 06:30:00

CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer," was recently published by Comins et al in the journal Clinical Cancer Research (Clin Cancer Res 16(22):5564-5572). The paper reports final results from a combination REOLYSIN and docetaxel trial, (REO 010) designed to evaluate the anti-tumour...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related